Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProFertil
2024-518977-32-00Phase 3Authorised
- Sponsor
- Karolinska University Hospital
- Start
- Oct 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer, Acute Leukaemia, Hodgkin lymphoma (HL) and 4 more comparing Pamorelin (triptorelin) arm with Placebo arm (2 arms). Primary endpoint: Primary: AMH recovery at 12 months after end of treatment in breast cancer. Planned start Oct 2024; status: authorised.
02
Drugs
Pamorelin
03
Conditions
breast cancerAcute LeukaemiaHodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)osteosarcoma (OS)
Beyond the preview
Go deeper on 2024-518977-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518977-32-00.